12:00 AM
Sep 03, 2012
 |  BC Week In Review  |  Company News  |  Other News

Agennix cancer news

Agennix unveiled details of a restructuring announced last month, including headcount cuts of 37 (55%) to 30. Cuts will come from U.S. and Germany sites, and remaining employees will work on activities related to Agennix's talactoferrin program and assist in assessing strategic options. The restructuring, which Agennix expects to complete in November, will result in a...

Read the full 258 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >